{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li Z"],"funding":["The National Natural Science Foundation of China"],"pagination":["164"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11219989"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73(9)"],"pubmed_abstract":["T cell receptor-engineered T cells (TCR-Ts) therapy is promising for cancer immunotherapy. Most studies have focused on identifying tumor-specific T cell receptors (TCRs) through predicted tumor neoantigens. However, current algorithms for predicting tumor neoantigens are unreliable and many neoantigens are derived from non-coding regions. Thus, the technological platform for identifying tumor-specific TCRs using natural antigens expressed on tumor cells is urgently needed. In this study, tumor organoids-enriched tumor infiltrating lymphocytes (oeT) were obtained by repeatedly stimulation of autologous patient-derived organoids (PDO) in vitro. The oeT cells specifically responded to autologous tumor PDO by detecting CD137 expression and the secretion of IFN-γ using enzyme-linked immunospot"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures."],"pmcid":["PMC11219989"],"funding_grant_id":["32071413 and 82373261"],"pubmed_authors":["Li Y","Li Z","Ma L","Che X","Gao Z","Wang X","Liu T","Bai Y","Sun Y","Zhang Q","Deng H","Zhang P"],"additional_accession":[]},"is_claimable":false,"name":"Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures.","description":"T cell receptor-engineered T cells (TCR-Ts) therapy is promising for cancer immunotherapy. Most studies have focused on identifying tumor-specific T cell receptors (TCRs) through predicted tumor neoantigens. However, current algorithms for predicting tumor neoantigens are unreliable and many neoantigens are derived from non-coding regions. Thus, the technological platform for identifying tumor-specific TCRs using natural antigens expressed on tumor cells is urgently needed. In this study, tumor organoids-enriched tumor infiltrating lymphocytes (oeT) were obtained by repeatedly stimulation of autologous patient-derived organoids (PDO) in vitro. The oeT cells specifically responded to autologous tumor PDO by detecting CD137 expression and the secretion of IFN-γ using enzyme-linked immunospot","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T12:54:48.705Z","creation":"2025-04-04T12:54:48.705Z"},"accession":"S-EPMC11219989","cross_references":{"pubmed":["38954022"],"doi":["10.1007/s00262-024-03749-8"]}}